Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $19.6 million.

  • Tango Therapeutics' Gains from Investment Securities fell 1100.00% to -$20,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $223,000, marking a year-over-year increase of 737.14%. This contributed to the annual value of $19.6 million for FY2024, which is 17.21% up from last year.
  • As of FY2024, Tango Therapeutics' Gains from Investment Securities stood at $19.6 million, which was up 17.21% from $16.7 million recorded in FY2023.
  • Tango Therapeutics' Gains from Investment Securities' 5-year high stood at $19.6 million during FY2024, with a 5-year trough of $4.1 million in FY2020.
  • Over the past 3 years, Tango Therapeutics' median Gains from Investment Securities value was $16.7 million (recorded in 2023), while the average stood at $16.4 million.
  • Data for Tango Therapeutics' Gains from Investment Securities shows a peak YoY surged of 128.91% (in 2021) over the last 5 years.
  • Tango Therapeutics' Gains from Investment Securities (Yearly) stood at $4.1 million in 2020, then soared by 128.91% to $9.4 million in 2021, then spiked by 37.89% to $12.9 million in 2022, then rose by 29.49% to $16.7 million in 2023, then rose by 17.21% to $19.6 million in 2024.